Ocera Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

OCRX 5.68 -0.03 (-0.53%)
price chart
Ocera Therapeutics Finally Ready To Reward Investors
Earlier this year investor confidence surrounding Ocera was high as the company's lead product OCR-002 was underway in two Phase 2a sponsored studies in acute liver failure and hyperammonemia in upper GI bleed.
Ocera Therapeutics Promotes Michael Byrnes to Chief Financial Officer
3, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical-stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the appointment of Michael Byrnes as chief financial officer.
Related articles »  
Ocera Therapeutics Well-Capitalized After The Merger
Ocera Therapeutics (NASDAQ:OCRX) announced the closing of a merger with Tranzyme on July 15. Immediately following the closing of the merger, certain of the Ocera investors invested approximately $20 million in the company through a private ...
Ocera Therapeutics (OCRX) Worth Watching: Stock Up 9.4%
Ocera Therapeutics, Inc. (OCRX - Snapshot Report) was a big mover last session with its shares rising over 9% on the day.
Ocera Therapeutics (OCRX) Worth Watching: Stock Up 9.4% - Tale of the Tape  Nasdaq
Related articles »  
Ocera Therapeutics (OCRX) Shares March Higher, Can It Continue?
Investors certainly have to be happy with Ocera Therapeutics Inc (OCRX - Snapshot Report) and its short term performance. After all, the stock has jumped by 8.2% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well.
Related articles »  
Ocera Therapeutics: A Potential Multibagger Biopharmaceutical Company
Ocera Therapeutics [Nasdaq: (NASDAQ:OCRX)] announced the initiation of its phase 2b double blind, controlled, randomized clinical trial in early January 2014.
Related articles »  
Ocera Therapeutics Announces Appointment of Gaurav Aggarwal, MD, as Chief ...
PALO ALTO, Calif., May 2, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that Gaurav Aggarwal, M.D.
Related articles »  
Ocera Therapeutics Announces Completion of Merger With Tranzyme
SAN DIEGO, July 15, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. ("Ocera"), a clinical stage biopharmaceutical company developing novel therapeutics for orphan liver diseases, and Tranzyme, Inc. (Nasdaq:TZYM) ("Tranzyme") today announced ...
Related articles »  
Ocera Therapeutics' (OCRX) CEO Linda Grais on Q3 2014 Results - Earnings ...
Welcome to Ocera Therapeutics Q3 Earnings Call. This call is being webcast live on the Events page of the Investor section of Ocera's Web site at www.ocera.com. Pardon me its www.ocerainc.com. This call is the property of Ocera and any recording, ...
Ocera Therapeutics (OCRX) Announces Quarterly Earnings Results, Beats ...  WKRB News
Ocera Reports Third Quarter 2014 Financial Results  CNNMoney
Related articles »  
Ocera Therapeutics Announces Appointment of Steven P. James to Board
PALO ALTO, Calif., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Steven P. James has been ...
Related articles »